

# Joseph N Jarvis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7879524/publications.pdf>

Version: 2024-02-01

124  
papers

7,396  
citations

81900

39  
h-index

60623

81  
g-index

130  
all docs

130  
docs citations

130  
times ranked

5020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	2
2	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2022, 386, 1109-1120.	27.0	119
3	Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
4	Human Herpesvirus-6 Detection in Cerebrospinal Fluid on the BioFire FilmArray Meningitis/Encephalitis Panel in a High Human Immunodeficiency Virus-Prevalence African Setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	3
5	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022, 305, 115082.	3.8	5
6	Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. <i>Biomedicines</i> , 2022, 10, 1399.	3.2	3
7	Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapyâ€“Experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana. <i>Clinical Infectious Diseases</i> , 2021, 72, 1745-1754.	5.8	10
8	Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 233-244.	4.4	14
9	Outcomes of Reflex Cryptococcal Antigen (CrAg) Screening in Human Immunodeficiency Virus (HIV)-Positive Patients With CD4 Counts of 100â€“200 Cells/ÂµL in Botswana. <i>Clinical Infectious Diseases</i> , 2021, 72, 1635-1638.	5.8	7
10	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 16-18.	9.1	18
11	The prevalence of laboratory-confirmed <i>Pneumocystis jirovecii</i> in HIV-infected adults in Africa: A systematic review and meta-analysis. <i>Medical Mycology</i> , 2021, 59, 802-812.	0.7	11
12	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101â€“200 cells/ÂµL in Botswana. <i>Wellcome Open Research</i> , 2021, 6, 55.	1.8	0
13	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021, 11, e039191.	1.9	7
14	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009376.	3.0	8
15	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.9	9
16	Five years after Treat All implementation: Botswanaâ€™s HIV response and future directions in the era of COVID-19. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1275.	0.9	5
17	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	5.8	13
18	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020, 70, 1683-1690.	5.8	38

#	ARTICLE	IF	CITATIONS
19	Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus “Treat All” Adoption in Uganda. <i>Clinical Infectious Diseases</i> , 2020, 71, 2497-2499.	5.8	6
20	HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 422-437.	1.9	2
21	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020, 99, e22606.	1.0	4
22	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020, 34, 1425-1428.	2.2	9
23	Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study. <i>Lancet HIV</i> , 2020, 7, e545-e553.	4.7	23
24	Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. <i>Lancet HIV</i> , 2020, 7, e422-e433.	4.7	17
25	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	10
26	HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020, 12, 1404.	3.3	2
27	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	19
28	Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25416.	3.0	39
29	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.9	12
30	Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes. <i>Aids</i> , 2020, 34, 2223-2230.	2.2	15
31	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	5.8	62
32	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naïve Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts $\leq 100/\mu\text{L}$ : A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 688-698.	5.8	38
33	Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019, 219, 344-346.	4.0	8
34	HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. <i>Lancet Infectious Diseases</i> , 2019, 19, 793-794.	9.1	5
35	Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. <i>Lancet Infectious Diseases</i> , 2019, 19, 740-749.	9.1	25
36	Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey. <i>Journal of Infection</i> , 2019, 79, 212-219.	3.3	15

#	ARTICLE	IF	CITATIONS
37	Reply to Rajasingham and Boulware. Clinical Infectious Diseases, 2019, 69, 732-735.	5.8	2
38	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. BMJ Open, 2019, 9, e026288.	1.9	6
39	Comparison of knowledge of HIV status and treatment coverage between non-citizens and citizens: Botswana Combination Prevention Project (BCPP). PLoS ONE, 2019, 14, e0221629.	2.5	4
40	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. Aids, 2019, 33, 1539-1541.	2.2	1
41	Causes of Pediatric Meningitis in Botswana: Results From a 16-Year National Meningitis Audit. Pediatric Infectious Disease Journal, 2019, 38, 906-911.	2.0	8
42	Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya. Aids, 2019, 33, 1404-1406.	2.2	2
43	Emerging concepts in HIV-associated cryptococcal meningitis. Current Opinion in Infectious Diseases, 2019, 32, 16-23.	3.1	24
44	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	9.1	63
45	Recent advances in managing HIV-associated cryptococcal meningitis. F1000Research, 2019, 8, 743.	1.6	11
46	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. Wellcome Open Research, 2019, 4, 144.	1.8	12
47	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. Wellcome Open Research, 2019, 4, 144.	1.8	9
48	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. Southern African Journal of HIV Medicine, 2019, 20, 1030.	0.9	33
49	Letters from Botswana: Diagnostic Challenges of Deep Fungal Infections. Skinmed, 2019, 17, 341-343.	0.0	0
50	CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2018, 66, S152-S159.	5.8	84
51	A tale of two countries: progress towards <scp>UNAIDS</scp> 90â€90â€90 targets in Botswana and Australia. Journal of the International AIDS Society, 2018, 21, e25090.	3.0	26
52	Fully 3D printed integrated reactor array for point-of-care molecular diagnostics. Biosensors and Bioelectronics, 2018, 109, 156-163.	10.1	71
53	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. Clinical Infectious Diseases, 2018, 66, 686-692.	5.8	76
54	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials, 2018, 19, 649.	1.6	41

#	ARTICLE	IF	CITATIONS
55	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. MBio, 2018, 9, .	4.1	5
56	High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin Bâ€“Based Therapy Under Routine Care Conditions in Africa. Open Forum Infectious Diseases, 2018, 5, ofy267.	0.9	30
57	Neurological Sequelae of Adult Meningitis in Africa: A Systematic Literature Review. Open Forum Infectious Diseases, 2018, 5, ofx246.	0.9	12
58	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 574-578.	2.1	19
59	Treatment for HIV-associated cryptococcal meningitis. The Cochrane Library, 2018, 2018, CD005647.	2.8	33
60	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. G3: Genes, Genomes, Genetics, 2017, 7, 1165-1176.	1.8	79
61	Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis. Clinical Infectious Diseases, 2017, 65, 779-786.	5.8	56
62	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infectious Diseases, The, 2017, 17, 873-881.	9.1	1,559
63	Modulating host immune responses to fight invasive fungal infections. Current Opinion in Microbiology, 2017, 40, 95-103.	5.1	32
64	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nature Reviews Neurology, 2017, 13, 13-24.	10.1	344
65	Neurosyphilis in Africa: A systematic review. PLoS Neglected Tropical Diseases, 2017, 11, e0005880.	3.0	20
66	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	3.0	47
67	Immune correlates of HIV-associated cryptococcal meningitis. PLoS Pathogens, 2017, 13, e1006207.	4.7	19
68	Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana. Journal of Global Oncology, 2016, 2, 47-50.	0.5	12
69	HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. Current Clinical Microbiology Reports, 2016, 3, 92-102.	3.4	21
70	Forgotten but not gone: HIV-associated cryptococcal meningitis. Lancet Infectious Diseases, The, 2016, 16, 756-758.	9.1	14
71	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials, 2015, 16, 276.	1.6	22
72	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0003847.	3.0	94

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. <i>PLoS Pathogens</i> , 2015, 11, e1004754.	4.7	117
74	Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. <i>Current Tropical Medicine Reports</i> , 2015, 2, 81-89.	3.7	38
75	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7224-7231.	3.2	99
76	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. <i>Clinical Infectious Diseases</i> , 2014, 58, 736-745.	5.8	299
77	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
78	Rapid Diagnosis of Cryptococcal Meningitis by Use of Lateral Flow Assay on Cerebrospinal Fluid Samples: Influence of the High-Dose “Hook” Effect. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4172-4175.	3.9	45
79	Vitamin D deficiency in HIV-infected South Africans: Common, and not associated with susceptibility, immune response, or outcome in HIV-associated cryptococcal meningitis. <i>International Journal of Infectious Diseases</i> , 2014, 21, 284.	3.3	1
80	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	8.2	130
81	Artemisinin therapy and severe delayed haemolysis. <i>Lancet</i> , The, 2013, 382, 180.	13.7	22
82	The Phenotype of the Cryptococcus-Specific CD4+ Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1817-1828.	4.0	113
83	Acute Schistosomiasis in Travelers: 14 Years' Experience at the Hospital for Tropical Diseases, London. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 1032-1034.	1.4	26
84	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 26-34.	3.1	60
85	Clinical aspects of visceral leishmaniasis in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 1-9.	3.1	81
86	Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. <i>Tropical Medicine and International Health</i> , 2013, 18, 1075-1079.	2.3	46
87	Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa. <i>PLoS ONE</i> , 2013, 8, e69288.	2.5	112
88	Reply to Lee and Newton. <i>Clinical Infectious Diseases</i> , 2012, 55, 1745-1746.	5.8	0
89	Adjunctive interferon- $\gamma$ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1105-1113.	2.2	238
90	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1363-1370.	2.2	73

#	ARTICLE	IF	CITATIONS
91	Cryptococcal Antigen Screening and Preemptive Therapy in Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 374-379.	1.2	52
92	British <scp>HIV</scp> Association opportunistic infection guidelines: in defence of amphotericin <scp>B</scp> deoxycholate. <i>HIV Medicine</i> , 2012, 13, 636-637.	2.2	8
93	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	5.8	127
94	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012, 64, 76-81.	3.3	69
95	Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2011, 53, 1019-1023.	5.8	266
96	Cryptococcal meningitis - a neglected killer. <i>South African Medical Journal</i> , 2011, 101, 244.	0.6	6
97	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. <i>South African Medical Journal</i> , 2011, 101, 232.	0.6	20
98	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011, 63, 484-486.	3.3	15
99	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010, 24, 612-614.	2.2	23
100	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010, 24, 1233-1235.	2.2	24
101	Outcomes of cryptococcal meningitis in antiretroviral naÃve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010, 60, 496-498.	3.3	42
102	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010, 10, 67.	2.9	222
103	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: The role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010, 100, 378.	0.6	40
104	Cryptococcal Antigen Screening for Patients Initiating Antiretroviral Therapy: Time for Action. <i>Clinical Infectious Diseases</i> , 2010, 51, 1463-1465.	5.8	35
105	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. <i>Clinical Infectious Diseases</i> , 2010, 51, 986-987.	5.8	7
106	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010, 24, 405-410.	2.2	64
107	Combination Flucytosine and HighâDose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010, 50, 338-344.	5.8	166
108	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010, 14, e310-e312.	3.3	28



#	ARTICLE	IF	CITATIONS
109	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. Clinical Infectious Diseases, 2009, 49, 702-709.	5.8	201
110	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. Clinical Infectious Diseases, 2009, 49, 812-813.	5.8	3
111	Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa. Clinical Infectious Diseases, 2009, 48, 856-862.	5.8	283
112	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids, 2009, 23, 1182-1183.	2.2	83
113	Thalidomide Treatment for Refractory HIV-associated Colitis: A Case Series. Clinical Infectious Diseases, 2008, 47, 133-136.	5.8	38
114	Pulmonary Cryptococcosis. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 141-150.	2.1	81
115	Managing cryptococcosis in the immunocompromised host. Current Opinion in Infectious Diseases, 2008, 21, 596-603.	3.1	47
116	HIV-associated cryptococcal meningitis. Aids, 2007, 21, 2119-2129.	2.2	213
117	Lactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration. Clinical Infectious Diseases, 2006, 42, 1719-1725.	5.8	21
118	Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malaria Journal, 2005, 4, 1.	2.3	155
119	Case reports: pernicious complications of benign tertian malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 551-553.	1.8	32
120	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. Wellcome Open Research, 0, 6, 140.	1.8	3
121	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1
122	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. Wellcome Open Research, 0, 6, 140.	1.8	0
123	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101-200 cells/ $\mu$ L in Botswana. Wellcome Open Research, 0, 6, 55.	1.8	0
124	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. Wellcome Open Research, 0, 6, 140.	1.8	1